Title Page 1

2	Prevalence of class A ESBL, class B and D carbapenemase
3	encoding genes (CTX-M, TEM, SHV, NDM, IMP, OXA-48) in
4	gram-negative bacterial pathogens isolated from various
5	clinical samples collected from northern region of United Arab
6	Emirates.
7	Premalatha Ragupathi ¹ ¶, Vaneezeh Khamisani ¹ ¶, Aisha Fadila Sadiq ¹ ¶, Mariam Aylu Mobiddo ¹ ¶,
8	Nazeerullah Rahamathullah ^{1,2} ¶*, Sovan Bagchi ¹ , Ala Kamian ¹ , Nasir Parwaiz ³ , Mohammad
9	Shahid Akhtar ³
10	
11	¹ Department of Biomedical Sciences, College of Medicine, Gulf Medical University, Ajman,
12	UAE.
13	² Thumbay Research Institute for Precision Medicine, College of Medicine, Gulf Medical
14	University, Ajman, UAE.
15	³ Thumbay Laboratory, Thumbay University Teaching Hospital, Gulf Medical University, Ajman,
16	UAE.
17	*Corresponding author
18	dr.nazeer@gmu.ac.ae (NR)

[¶]These authors contributed equally to this work 19

18

20 Short Title: Class A ESBL genes *bla_{CTX-M}*, *bla_{TEM}*, *bla_{SHV}* and class B & D carbapenemase

21 encoding genes bla_{NDM} , bla_{IMP} , bla_{OXA-48} .

22 Abstract

23 **Objective**

24 The aim of this study was to assess the prevalence of class A ESBL, class B and D carbapenemase

encoding genes (*bla_{CTX-M}*, *bla_{TEM}*, *bla_{SHV}*, *bla_{NDM}*, *bla_{IMP}* and *bla_{OXA-48}*) in gram-negative bacterial

26 pathogens isolated from various clinical samples collected from northern region of UAE.

27 Methods

28 A laboratory based experimental study was conducted from October 14, 2021, to June 30, 2022. A total of 3670 various clinical samples (urine, blood, pus, and sputum) were obtained from 29 patients attending the in and out-patient departments of Thumbay University Hospital and various 30 31 other hospitals of Northern Emirates of UAE, processed for routine bacterial culture examination 32 and determined their antibiotic sensitivity pattern especially ESBL and carbapenem resistance using MicroScan Neg Breakpoint Combo 50 panel. Molecular detection of class A ESBL, class B 33 34 and D carbapenemase encoding genes ($blac_{TX-M}$, bla_{TEM} , bla_{SHV} , bla_{NDM} , bla_{IMP} & bla_{OXA-48}) were 35 performed on the ESBL and carbapenemase producing gram negative bacteria. Partial genomic 36 sequencing and phylogenetic tree analysis was performed on the most predominant ESBL gene 37 bla_{CTX-M}.

38 **Results**

In total, 1098 bacterial cultures were obtained, of which 833 were gram negative bacteria and 39 40 among them, 209 (25.1%) were ESBL producers and 40 (4.8%) were both ESBL and 41 carbapenemase producers. In all the 249 bacterial isolates, the ESBL and carbapenemase encoding genes (bla_{CTX-M} , bla_{TEM} , bla_{SHV} , bla_{NDM} & bla_{IMP}) were detected except bla_{OXA-48} . The bla_{CTX-M} 42 43 (n=72) was the predominantly harbored gene followed by bla_{TEM} (n=56) and bla_{SHV} (n=29), 44 mostly detected in E. coli (n=157), then K. pneumoniae (n=41), P. aeruginosa (n=18) & A. 45 *baumannii* (n=7). The *bla_{NDM}* & *bla_{IMP}* were detected in *K*. *pneumoniae* (n=4), *A*. *baumannii* (n=3) and P. aeruginosa (n=2) for bla_{IMP} . The gene combinations such as $bla_{CTX-M+TEM}$ (n=15), bla_{CTX-M+ 46 47 $_{M+SHV}$ (n=15), $bla_{CTX-M+TEM}+bla_{SHV}$ (n=6) were co-harbored in 36 E. coli and in the K. pneumoniae, 48 the $bla_{CTX-M+TEM}$ (n=15), $bla_{CTX-M+SHV}$ (n=15), $bla_{TEM+SHV}$ (n=3), $bla_{TEM+NDM}$ (n=1) were detected. The $bla_{CTX-M+TEM}$, $bla_{CTX-M+SHV}$ & $bla_{CTX-M+TEM+SHV+IMP}$ were detected in one *P. aeruginosa* and in 49 50 one A. baumannii, the $bla_{TEM+NDM}$, $bla_{TEM+IMP}$ & $bla_{CTX-M+TEM+SHV+IMP}$ were detected.

51 Conclusion

The highest bacterial culture positivity was detected in the urine samples. 25.1% of the Gram-ve bacteria were only ESBL producers and 4.8% were both the ESBL & carbapenemase producers. 44.5% of ESBL & carbapenemase producing bacteria harbored the *bla_{CTX-M}* and mostly detected in the *E. coli*, then *K. pneumoniae* and *P. mirabilis*. Multiple gene combinations were detected in 5% *P. aeruginosa*, 10% *A. baumannii* and 3.82% *E. coli*. This finding highlights the importance of molecular detection of ESBL & carbapenemase producing genes to emphasize the monitor and control the development of multi drug resistant Gram-ve bacterial pathogens.

59 Keywords: *E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis, A. baumannii*, Multidrug resistant,
60 ESBL genes, carbapenemase producing genes.

61 Introduction

62 Antibiotic-resistant bacterial infections are now a serious problem worldwide and have become a global threat to public health, animal production, and environmental health. Globally, more than 7 63 64 million people die every vear from multidrug resistant bacterial infection. It is estimated that 10 million people will die from antimicrobial resistant (AMR) infections by 2050.[1, 2] Over 65 66 prescribing antibiotics, irresponsible usage and not adhering to prescription are some of the leading 67 causes of development of antibiotic resistance.[3, 4] Gram-negative bacteria are more prone to develop antibiotic resistance than other bacteria and due to the enhanced use of beta-lactam 68 69 antibiotics, the bacterial pathogens have developed to produce the enzyme beta lactamase using 70 plasmid which counteract the beta lactam compound. [5, 6]

71 The rapid spread of antibiotic resistance genes among the gram-negative bacteria facilitated by the mobile genetic elements; plasmids and transposons are responsible for resistance towards a broad 72 73 spectrum of antibiotics and have established the pivotal role in the dissemination of AMR.[7] 74 Spreading of the plasmid mediated beta lactamase in gram negative bacterial pathogens is known 75 as extended spectrum of beta lactamase (ESBL). Molecular classification of the β-lactamases 76 divided into A, B, C, D enzymes [8, 9]. The class A enzyme producing genes are bla_{TEM} , bla_{SHV} and $bla_{CTX-M}[10]$. The bla_{TEM} is commonly found in Gram-negative bacteria [11, 12] and the gene 77 78 bla_{CTX-M} produces an enzyme called cefotaximase that inhibits the activity of the cefotaxime and as of March 2019, over 172 CTX-M types have been identified and described [13-15]. The gene 79

bla_{SHV} and *bla_{TEM}* are structurally similar and as of February 2018, over 223 TEM and 193 SHV
types have been listed in public databases [16].

The ESBL producers have emerged as a major source of resistance among the gram-negative 82 83 bacteria, more predominantly in the Escherichia coli and Klebsiella pneumoniae; thereby 84 becoming a global concern. [17] K. pneumoniae strains that produce ESBLs and carbapenemase 85 have a worldwide distribution and cause multidrug-resistant (MDR) infections in many countries. 86 [7, 18, 19]. Carbapenems are one of the few drugs that are useful for the treatment of MDR gramnegative bacterial infections. The emergence of carbapenem resistance in Enterobacteriaceae 87 family is a serious public health concern due to the large spectrum of resistant genes and lack 88 89 therapeutic options. [20,21] Carbapenem-hydrolyzing β -lactamases belonging to molecular class A (e.g., KPC, GES, IMI, SME), class B (e.g. IMP, VIM, NDM, GIM) and class D (e.g. OXA-23 90 91 & OXA- 48) and are the main source of antibiotic resistance in *Enterobacteriaceae*.[20-22]

92 Furthermore, ESBL developing species show co-resistance to many other groups of antibiotics and 93 limiting therapeutic options. As a result, in recent past, emergence of multidrug resistant (MDR) 94 gram-negative bacterial infections have increased significantly and it is mainly acquired by 95 ESBLs. [6,7,23] Nevertheless there is still a scarcity of data on the prevalence of ESBLs and 96 carbapenemase producing genes in patients' samples in the UAE. Although some data have been 97 published from this region and neighbouring countries, limited number of studies are available on 98 the genes *bla_{TEM}*, *bla_{SHV}*, *bla_{CTX-M}*, *bla_{NDM}*, *bla_{IMP}* and *bla_{OXA-48}* but no detailed studies on the 99 prevalence and harboring of multiple genes in the MDR bacteria have yet been performed in the 100 UAE. So, the current research focuses on the prevalence of class A ESBL (*bla_{TEM}*, *bla_{SHV}* & *bla_{CTX}*-101 _M) and class B & D carbapenemase encoding genes (bla_{NDM} , bla_{IMP} , bla_{OXA-48}) in gram-negative 102 bacterial pathogens isolated from various clinical samples collected from northern region of UAE.

103 Determining the prevalence of class A ESBL and class B & D carbapenemase producing genes in

104 gram-negative bacterial pathogens is critical for effective treatment of infections caused by the

105 MDR organisms especially in ICU and in-patients with co-morbidity cases.

106 Methods

107 Ethical Approval

The present study was approved by the Institutional Review Board (IRB) of Gulf Medical University, Ajman, UAE. The approval letter from the IRB, dated October 14, 2021, indicated that the study had already received approval in the IRB meeting of September 2021 (Ref.no.IRB/COM/STD/98/Oct.2021). The study design and protocol followed the Good Clinical Practice (GCP) guidelines 2021, National Drug Abuse Treatment Clinical Trials Network.

113 Study Design

A laboratory based experimental study was conducted on various clinical samples such as urine,
blood, pus, and sputum received from various hospitals of Northern Emirates of the UAE to the
Department of Microbiology at Thumbay Laboratory, Thumbay University Hospital (TUH),
Ajman, UAE.

118 Data collection & Clinical sample processing

In accordance with the IRB approval, the patients' clinical samples and other details were collected
from Thumbay Laboratory, TUH, from September 02, 2021, to June 20, 2022. But laboratory

analysis was performed following receipt of the IRB approval from October 14, 2021, to June 30,2022.

123 Study populations

All the clinical samples were received and collected from the patients who are attending internal
medicine out-patient and in patient department of TUH and other hospitals of Northern Emirates
of the UAE. All the samples were received by the phlebotomy department and sent to the
Microbiology department at Thumbay Laboratory, TUH to culture bacterial pathogens, staining
and antibiotic sensitivity test of the isolated pathogens, and molecular detection of class A ESBL
genes *bla_{CTX-M}*, *bla_{SHV}*, *bla_{TEM}* and carbapenemase producing genes *bla_{NDM}*, *bla_{IMP}*, and *bla_{OX4-48}*.
Upon arrival, the samples were processed for further laboratory tests.

131 Bacterial isolation and staining

The clinical samples were plated on MacConkey's agar to isolate the bacterial colony belongs to the *Enterobacteriaceae* family, Blood agar for gram positive bacterial species, Cysteine-Lactose Electrolyte Deficient (CLED) agar for urinary tract pathogens and Cetrimide Agar for *Pseudomonas* species isolation. All the culture plates were incubated overnight at 37°C for 18-24 hours. After the isolation of bacterial colonies from the different culture media, they were stained by Gram staining to identify them whether gram-negative or gram-positive bacteria.

138 Bacterial identification and antibiotic sensitivity test

MicroScan WalkAway automated detection system was used to identify bacterial pathogens andto determine their ESBL and MDR nature. The bacterial inoculum was prepared from single

141 colonies of isolated bacteria by using the Prompt[™] Inoculation System-D (Beckman Coulter, 142 Brea, CA, USA), consisting of a wand designed to hold a specific quantity of bacteria and a 30 ml 143 Prompt[™] Inoculation Water bottle (BECKMAN COULTER, Brea, CA, USA). The inoculum was 144 suspended thoroughly, poured in to a RENOK inoculator tray and then transferred in to MicroScan 145 Neg Breakpoint Combo 50 panel for Gram-negative organism (BECKMAN COULTER) using 146 RENOK inoculator (BECKMAN COULTER). The plate was incubated at 16 – 18°C in MicroScan 147 WalkAway automated system DxM 1096 (BECKMAN COULTER). Table 1 & 1a demonstrate 148 various tests performed on the MicroScan Neg Breakpoint Combo 50 panel. The Beckman Coulter 149 MicroScan LabPro software WalkAway 9631049 was used to evaluate the gram-negative bacterial 150 pathogens on their biochemical utilization and antibiotic sensitivity pattern especially ESBL and 151 carbapenem resistant strains. The details of the MicroScan Neg Breakpoint Combo 50 panel for 152 Gram-negative organisms are given in Supplementary table1a & 1b.

153 Detection of Class A ESBL and Class B & D carbapenemase encoding

154 genes

155 After the identification of ESBL and MDR strains, they were sub-cultured in sterile double strength Muller Hinton broth at 37°C for 24 hours for bacterial DNA extraction with the G-spinTM for 156 157 Genomic DNA extraction kit (iNtRON). The DNA extracts positive for the 16SrRNA gene in PCR assays were processed for the presence of the class A ESBL genes bla_{SHV}, bla_{CTX-M}, bla_{TEM} and 158 159 carbapenem resistant genes *bla_{NDM}*, *bla_{IMP}*, and *bla_{OXA-48}* with consensus primers in a VeritiTM 96-160 well Thermal cycler (Applied Bio-systemsTM). The PCR assays were performed with 161 Thermoscientific PCR Master mix kit (ThermoFisher). The PCR primers and their specifications 162 are provided in the Table 1. Primers of all the class A ESBL and carbapenem resistant genes were

163 synthesized by e-oligos, Gene LinkTM, NY, USA. The PCR products underwent agarose gel

164 electrophoresis to separate the fragments of DNA and visualized the target genes which are

- 165 pointed in Fig $\underline{1}$.
- **Table 1**. PCR primers and their specifications.

167

Gene type	Amplicon	Primer sequence (5' – 3')	Amplicon size (bp)	Annealing temperature °C	Reference	
	bla _{CTX-M}	F -SCSATGTGCAGYACCAGTAA R -ACCAGAAYVAGCGGBGC	585	58		
ESBL gene primers	bla _{TEM}	F -ATGAGTATTCAACATTTCCG R -CCAATGCTTAATCAG TGAGG	858	50	[<u>24]</u>	
	bla _{SHV}	F -ATGCGTTATATTCGCCTGTG R -AGCGTTGCCAGTGCTCGATC	862	58		
	bla _{NDM}	F -GGTTTG GCGATCTGGTTTTC R -CGGAATGGCTCATCACGATC	621	57	[<u>26</u>]	
Carbapenemase genes primers	bla _{IMP}	F -CTACCGCAGCAGAGTCTTTG R -AACCAGTTTTGCCTTACCAT	587	56	[25]	
	bla _{OXA48}	F -GCGTGGTTAAGGATGAACAC R -CATCAAGTTCAACCCAACCG	438	57	[<u>27]</u>	
Control primer	16S rRNA gene	F -AGAGTTTGATCMTGGCTCAG R -ACGGHTACCTTGTTACGACTT	1,500	55	[<u>24</u>]	

168 Fig 1. Detection of bla_{CTX-M} , bla_{TEM} , bla_{SHV} , bla_{IMP} & bla_{NDM} bands in 1% agarose gel

169 Genomic sequencing and phylogenetic tree relationships of the

- 170 *bla_{CTX-M}*
- 171 Partial gene sequencing of the *bla_{CTX-M}* of the *E. coli* was done by Sanger sequencing method and

172 the sequenced product was compared with existing gene sequences in GenBank, NCBI. The

173 cladogram of the phylogenetic tree relationship of the bla_{CTX-M} was constructed using Mega 11

software. It was constructed using the Dice coefficient with a 1% tolerance limit and 1% optimization. Cluster relatedness of collected isolates with \geq 70% similarity was considered to indicate an identical pattern type [28, 29].

177 Statistical Analysis

- 178 Data were analyzed using the statistical package SPSS software version 28.0 (SPSS Inc., Chicago,
- 179 IL, USA). Descriptive data were represented as mean ± SD. Pearson's chi-square test was
- 180 performed in tables 3 and 4 with p-value <0.05 considered as statistically significant.

181 **RESULTS**

182 Bacterial isolation and staining

A total of 3670 samples were collected and processed for the routine bacterial culture. Among 183 184 them, pus (n=469;12.7%), blood (n=879;24%), sputum (n=352;9.6%), urine (n=1970; 53.7%) samples were received, out of which, 1098 samples (29.9%) were positive and 2572 (70.1%) were 185 186 negative for the bacterial culture. In that culture positive samples, the highest bacterial culture 187 positivity was detected in the urine samples (49.1%; n=540), then in the pus (23%; n=253), blood 188 (10.8%; n=119) and sputum (16.9%; n=186). In the 10986 culture positive samples, 833 (75.9%) 189 were gram-negative and 265 (24.1%) were gram-positive bacteria and their details are given in 190 Table 2; Fig 2.

191

192 Bacterial identification and antibiotic susceptibility test

- Among the gram-negative bacterial isolates, 249 (29.9%) were ESBL (n=209; 25.1%) and both
- 194 ESBL & carbapenemase producers (n=40; 4.8%). Among the 249 bacterial isolates, 157 (63.1%)
- 195 E. coli, 45 (18.1%) K. pneumoniae, 20 (8.0%) Pseudomonas aeruginosa, 17 (6.8%) Proteus
- 196 *mirabilis,* and 10 (4.0%) *Acinetobacter baumanii* were encountered and provided in <u>Table 3</u>; Fig
- 197 <u>3</u>.
- **Table 2.** No. of various clinical samples for positive bacterial growth.

Clinical	bacteria	es for positive ll growth (29.92%)	No. of samples for negative	Pearson's		
samples n= 3670 (%)	Gram negative bacterial growth n= 833 (75.86%)	Gram positive bacterial growth n=265 (24.14%)	bacterial growth n=2572 (70.08%)	Chi-square test		
Urine n= 1970 (53.7%)	503 (60.4%)	37 (13.96%)	1430 (55.59%)			
Blood n= 879 (23.93%)	48 (5.8%)	71 (26.8%)	760 (29.54%)	<0.0001		
Pus n= 469 (12.8%)	111 (13.3%)	142 (53.58%)	216 (8.39%)	<0.0001		
Sputum n= 352 (9.6%)	171 (20.53%)	15 (5.66%)	166 (6.45%)			

199

Fig 2. No. of Gram -ve and gram +ve bacteria isolated from various clinical samples.

201

202

203

Gram	Г	otal no. of ba	cteria (<i>n=833</i>)		- Pearson's		
negative bacterial isolates	Urine n=503 (%)	Blood n=48 (%)	Pus n=111 (%)	Sputum <i>n</i> =171(%)	Chi-square test		
E. coli	354 (70.37%)	8 (16.66%)	25 (22.52%)	7 (4.1%)			
K. pneumoniae	116 (23.06%)	15 (31.25%)	35 (31.53%)	34 (19.9%)			
P. aeruginosa	15 (2.98%)	9 (18.75%)	19 (17.11%)	86 (50.29%)	< 0.0001		
P. mirabilis	12 (2.39%)	0	24 (21.62%)	4 (2.34%)			
A. baumannii	6 (1.19%)	16 (33.33%)	8 (7.21%)	40 (23.4%)			

Table 3. Total no. of Gram-ve bacteria isolated from various clinical samples.

205

Fig 3. Total no. of *E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis* and *A. baumannii* in various
clinical samples.

208 The ESBL E. coli (n=157) had shown 100% resistance to cefotaxime and ceftazidime, high -209 medium resistance rates to Ampicillin/sulbactam, ampicillin, Aztreonam, cefazolin, cefepime, 210 cefuroxime, (97.5%) & Amoxicillin+clavulanate (92.5%), norfloxacin (63.7%), 211 trimethoprim/Sulfamethoxazole (58.6%), ciprofloxacin (51.6%) and levofloxacin (46.5%). Lower 212 resistance rate to gentamycin (14.7%), tobramycin (12.7%) and least resistance rate to cefoxitin 213 (7.6%) and absolute sensitivity to imipenem, meropenem, nitrofurantoin, piperacillin/tazobactam, 214 tigecycline, amikacin, ertapenem, colistin. In the K. pnuemoniae isolates (n=45), all of them shown 215 100% resistant to the antibiotics: ampicillin, ampicillin + sulbactam, aztreonam, cefazolin, 216 cefepime, and cefuroxime. 89% of them were resistant to amoxycillin + clavulanate and 217 cefotaxime, whereas 66.7% - 55.6% of them were resistant to Ceftazidime, nitrofurantoin, 218 norfloxacin, trimethoprim/sulfamethoxazole. 33.3% of the bacteria were resistant to the drug 219 gentamycin. Nearly 22.2% of the bacteria were resistant to 9 drugs: levofloxacin, meropenem, 220 pipracillin+tazobactum, tigecycline, tobramycin, Amikacin, cefoxitin, ertapenem and

221 ciprofloxacin. 11.1% resistant to colistin, imipenem, norfloxacin. None of the K. pneumoniae had 222 shown 100% sensitive to the above-mentioned drugs. In case of ESBL producing P. mirabilis 223 (n=17), all were resistant to the following 10 antibiotics: tobramycin, amoxycillin+clavulanate, 224 ampicillin, cefepime, cefazolin, cefotaxime, cefuroxime, aztreonam, 225 trimethoprim/sulfamethoxazole and ceftazidime. 76.5% of them were shown resistance to the drugs gentamycin & amikacin. 52.9% were resistant to the drug norfloxacin, ciprofloxacin and 226 227 levofloxacin. The bacteria had shown intermediate resistance to the following drugs norfloxacin, 228 ciprofloxacin, gentamycin and ampicillin+sulbactam and they were 100% sensitive to imipenem, 229 meropenem, nitrofurantoin, piperacillin/tazobactam, Tigecycline, cefoxitin, ertapenem & colistin. 230 The bacteria *P. aeruginosa* (n=20) had shown 100% resistance to the drugs gentamycin, imipenem, 231 levofloxacin, meropenem, tobramycin, amikacin, cefepime, ceftazidime and ciprofloxacin, 65% 232 and 35% of them were resistant to the drugs pipracillin+tazobactum and Aztreonam respectively 233 and none of them were 100% sensitive to any antibiotics which are used in the test except colistin. 234 Similarly, the bacteria A. baumannii (n=10) had shown 100% resistance to 11 different drugs, 235 those were amikacin, cefepime, ciprofloxacin, gentamycin, imipenem, levofloxacin, meropenem 236 ceftazidime. 80% of the strains were resistant to ampicillin + sulbactam. and trimethoprim/sulfamethoxazole and tobramycin, and 30% of them were resistant to colistin. The 237 details are given in Table 4; Fig 4. 238

239 Table 4. Antibiotic sensitivity pattern of *E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis* and *A. baumannii* isolated from various

240 clinical samples.

Antibiotics		E. coli n= 157 ((%)		pneumon n=45 (%)			P. mirabili n=17 (%)			aerugin n=20 (%		A. baumannii n=10 (%)		
	S	I	R	S	Ι	R	S	Ι	R	S	Ι	R	S	Ι	R
Gentamicin	134 (85.4%)	0	23 (14.6%)	30 (66.7%)	0	15 (33.3%)	0	4 (23.5%)	13 (76.5%)	0	0	20 (100%)	0	0	10 (100%)
Imipenem	157 (100%)	0	0	40 (88.9%)	0	5 (11.1%)	17 (100%)	0	0	0	0	20 (100%)	0	0	10 (100%)
Levofloxacin	84 (53.5%)	0	73 (46.5%)	35 (77.8%)	0	10 (22.2%)	9 (52.9%)	0	8 (47.1%)	0	0	20 (100%)	0	0	10 (100%)
Meropenem	157 (100%)	0	0	35 (77.8%)	0	10 (22.2%)	17 (100%)	0	0	0	0	20 (100%)	0	0	10 (100%)
Nitrofurantoin	157 (100%)	0	0	40 (88.9%)	0	5 (11.1%)	17 (100%)	0	0	0	0	0	0	0	10 (100%)
Norfloxacin	57 (36.3%)	0	100 (63.7%)	40 (88.9%)	0	5 (11.1%)	0	8 (47.1%)	9 (52.9%)	0	0	0	0	0	10 (100%)
Piperacillin /Tazobactam	157 (100%)	0	0	35 (77.8%)	0	10 (22.2%)	17 (100%)	0	0	0	7 (35%)	13 (65%)	0	0	0
Tigecycline	157 (100%)	0	0	30 (66.7%)	5 (11.1%)	10 (22.2%)	17 (100%)	0	0	0	0	0	0	0	0
Tobramycin	130 (82.8%)	7 (4.5%)	20 (12.7%)	30 (66.7%)	5 (11.1%)	10 (22.2%)	0	0	17 (100%)	0	0	20 (100%)	0	0	10 (100%)
Trimethoprim/ Sulfamethoxazole	65 (41.4%)	0	92 (58.6%)	20 (44.4%)	0	25 (55.6%)	0	0	17 (100%)	0	0	0	0	2 (20%)	8 (80%)
Amikacin	157 (100%)	0	0	35 (77.8%)	0	10 (22.2%)	4 (23.5%)	0	13 (76.5%)	0	0	20 (100%)	0	0	10 (100%)
Amoxicillin/ Clavulanate	12 (7.6%)	0	145 (92.4%)	5 (11.1%)	0	40 (88.9%)	0	0	17 (100%)	0	0	0	0	0	0
Ampicillin/ sulbactam	4 (2.5%)	0	153 (97.5%)	0	0	45 (100%)	0	4 (23.5%)	13 (76.5%)	0	0	0	0	3 (30%)	7 (70%)

Ampicillin	0	0	153 (97.5%)	0	0	45 (100%)	0	0	17 (100%)	0	0	0	0	0	0
Aztreonam	4 (2.5%)	0	153 (97.5%)	14 <i>(31.1%)</i>	0	31 (68.8%)	0	0	17 (100%)	0	13 (65%)	7 (35%)	0	0	0
Cefazolin	4 (2.5%)	0	153 (97.5%)	0	0	45 (100%)	0	0	17 (100%)	0	0	0	0	0	0
Cefepime	4 (2.5%)	0	153 (97.5%)	0	0	45 (100%)	0	0	17 (100%)	0	0	20 (100%)	0	0	10 (100%)
Cefotaxime	0	0	157 (100%)	0	5 (11.1%)	40 (88.9%)	0	0	17 (100%)	0	0	0	0	0	0
Cefoxitin	138 (87.9%)	7 (4.5%)	12 (7.6%)	35 (77.8%)	0	10 (22.2%)	17 <i>(100%)</i>	0	0	0	0	0	0	0	0
Ceftazidime	0	0	157 (100%)	15 <i>(33.3%)</i>	0	30 (66.7%)	0	0	17 (100%)	0	0	20 (100%)	0	0	10 (100%)
Cefuroxime	0	4 (2.5%)	153 (97.5%)	0	0	45 (100%)	0	0	17 (100%)	0	0	0	0	0	0
Ciprofloxacin	76 (48.4%)	0	81 (51.6%)	30 (66.7%)	5 (11.1%)	10 (22.2%)	0	8 (47.1%)	9 (52.9%)	0	0	20 (100%)	0	0	10 (100%)
Ertapenem	157 (100%)	0	0	35 (77.8%)	0	10 (22.2%)	17 <i>(100%)</i>	0	0	0	0	0	0	0	0
colistin	157 (100%)	0	0	40 (88.9%)	0	5 (11.1%)	17 <i>(100%)</i>	0	0	20 (100%)	0	0	7 (70%)	0	3 (30%)

Fig 4. Heatmap of antibiotic sensitivity pattern of *E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa,* and *A. baumannii.*

244 Detection of Class A ESBL and Class B & D carbapenemase encoding

245 genes

All the ESBL and carbapenem resistant bacteria (n=249) had positive to all the 3 ESBL genes and 246 247 carbapenem resistant genes bla_{NDM} & bla_{IMP} either harbored single or multiple. Among the 249 248 isolates, the E. coli (n=157; 63.1%) harbored all the ESBL genes and among them, the bla_{CTX-M} 249 (n=72; 45.9%) was predominantly identified, then bla_{TEM} (n=59; 37.6%) and bla_{SHV} (n=31; 19.7%) 250 respectively. Of 157 E. coli, 20.33% (n=32) of them co-harbored more than one gene like bla_{CTX} . $_{M+TEM}$ or $bla_{CTX-M+SHV}$ or altogether. In that gene combination, the $bla_{CTX-M+TEM}$ (n=15; 9.55%) & 251 252 *bla_{CTX-M+SHV}* (*n*=15; 9.55%) were detected in 15 *E. coli* strains and all the 3 genes were identified 253 together in 3.8% of the *E. coli*. Similarly, the $bla_{CTX-M}(40\%; n=18)$ was the predominant gene even 254 in the MDR K. pneumoniae (n=45), followed by the bla_{TEM} (31.1%; n=14), bla_{SHV} (31.1%; n=14), 255 bla_{IMP} (13.33%; n=6) and bla_{NDM} (2.22%; n=1) respectively. The gene combinations such as either 256 the $bla_{CTX-M}+_{TEM}$ (n=14; 31.1%) or $bla_{CTX-M}+_{SHV}$ (n=10; 22.2%) or $bla_{TEM}+_{SHV}$ (6.6%; n=3) or 257 $bla_{TEM}+_{NDM}$ (2.22%; n=1) were detected in 62.22% of the K. pneumoniae. Likewise in the P. 258 aeruginosa, the genes bla_{CTX-M} and bla_{TEM} were detected in almost all the isolates. Of which, the 259 bla_{IMP} was detected in 7 (35%) strains and the bla_{SHV} was detected in 13 (65%) strains. The gene 260 combination such as $bla_{CTX-M+SHV}$ (5%; n=1) and $bla_{CTX-M+TEM+SHV+IMP}$ (5%; n=1) were detected in 261 10% of the organism. In the same manner, the gene bla_{CTX-M} was detected in all the 17 ESBL 262 positive P. mirabilis (100%), the bla_{TEM} was detected in 8 strains (47.1%) and among the 17 P. 263 *mirabilis* strains, 17.6% (n=3) of them had positive to both the genes ($bla_{CTX-M+TEM}$). The above

resistant genes holding bacterial strains were predominantly isolated from the urine and pus samples and the details are presented in Table 5; Fig 5.

266

- **Table 5.** Number of class A ESBL and class B carbapenemase encoding genes in number of *E*.
- 268 *coli, K. pneumoniae, P. aeruginosa, P. mirabilis* and *A. baumannii* isolated from various clinical

samples.

270

	FSBL	& Carbapenem		Single	gene de	tection					e gene de				
Clinical Samples (n=833)]	resistant G-ve bacteria n=249 (%)		bla _{TEM} n=85 (%)	bla _{SHV} n=45 (%)	bla _{NDM} n=3 (%)	bla _{IMP} n=6 (%)	bla _{CTX-M} +TEM n=33 (%)	bla _{CTX-M} +SHV n=26 (%)	bla _{TEM} +SHV n=3 (%)	bla _{CTX-M} +TEM +SHV n= 6 (%)	bla _{TEM} +NDM n=2 (%)	bla _{TEM} +IMP n=1 (%)	bla _{CTX-M} +TEM+SHV +IMP n=2 (%)	Pearson's Chi-square test
		<i>E. coli</i> <i>n=120 (76.9%)</i>	56 (46.7%)	44 <i>(36.7%)</i>	20 (16.7%)	0	0	11 (9.2%)	11 (9.2%)	0	6 (5%)	0	0	0	
Uning		K. pnuemoniae n=28 (17.9%)	8 (28.6%)	10 <i>(35.7%)</i>	7 (35.7%)	0	3 (21.4%)	8 (28.6%)	7 (25%)	3 (10.7%)	0	0	0	0	
Urine (<i>n=503</i>)	n=156 (31%)	P. aeruginosa n=5(3.2%)	2 (40%)	2 (40%)	1 (20%)	0	0	0	0	0	0	0	0	0	0.0147
		P. mirabilis n=3 (1.9%)	2 (66.7%)	1 <i>(33.3%)</i>	0	0	0	1 (33.3%)	0	0	0	0	0	0	
		A. baumannii (n=0)	0	0	0	0	0	0	0	0	0	0	0	0	
		E. coli n=7 (50%)	5 (71.4%)	1 <i>(14.3%)</i>	1 (14.3%)	0	0	1 (14.3%)	0	0	0	0	0	0	
DL		<i>K. pnuemoniae</i> n=2 (14.3%)	1 (50%)	1 (50%)	0	0	0	0	0	0	0	0	0	0	
Blood (<i>n=48</i>)	n=14 (29.2%)	P. aeruginosa n=2 (14.3%)	1 (50%)	0	1 (50%)	0	0	0	0	0	0	0	0	0	0.7933
		P. mirabilis (n=0)	0	0	0	0	0	0	0	0	0	0	0	0	
		A. baumannii n=3 (1.9%)	2 (66.7%)	1 <i>(33.3%)</i>	0	0	0	0	0	0	0	0	0	0	
D		<i>E. coli</i> n=25 (51%)	8 (32%)	10 (40%)	7 (28%)	0	0	3 (12%)	3 (12%)	0	0	0	0	0	
Pus (n=111)	n=49 (44.1%)	<i>K. pnuemoniae</i> n=7 (14.3%)	5 (71.4%)	1 (14.3%)	1 (14.3%)	0	0	3 (42.9%)	2 (28.6%)	0	0	0	0	0	0.0054
		P. aeruginosa n=3 (6.1%)	1 (33.3%)	1 (33.3%)	0	0	1 (33.3%)	0	0	0	0	0	0	0	

	P. mirabilis n=14 (28.6%)		4 (42.9%)	0	0	0	2 (14.3%)	0	0	0	0	0	0	
	A. baumannii (n=0)	0	0	0	0	0	0	0	0	0	0	0	0	
	E. coli n=5 (16.66%)	3 (60%)	1 (20%)	1 (20%)	0	0	0	1 (20%)	0	0	0	0	0	
	K. pnuemoniae n=8 (26.66%)	4 (50%)	2 (25%)	1 (12.5%)	1 (12.5%)	0	3 (37.5%)	1 (12.5%)	0	0	1 (12.5%)	0	0	
Sputum (<i>n</i> =171)	P. aeruginosa n=10 (33.33%)	3 (42.9%)	5 (28.6%)	1 <i>(14.3%)</i>	0	1 (14.3%)	1 (14.3%)	1 (14.3%)	0	0	0	0	1 (14.3%)	0.7354
	P. mirabilis (n=0)	0	0	0	0	0	0	0	0	0	0	0	0	
	A. baumannii n=7 (23.33%)	2 (28.6%)	1 (14.3%)	1 <i>(14.3%)</i>	2 (28.6%)	1 (14.3%)	0	0	0	0	1 (14.3%)	1 (14.3%)	1 (14.3%)	

Fig 5. Heatmap of frequency of class A ESBL and class B carbapenemase encoding genes in *E. coli, K. pneumoniae, P. aeruginosa, P.*

mirabilis and *A. baumannii* isolated from various clinical samples.

281	Table 6. Frequency of detection of class A	ESBL and class B carbapenema	se encoding genes in E. col	i, K. pneumoniae, P. aeruginosa,
	1 2	1	00	

P. mirabilis and *A. baumannii*.

ESBL &		Single §	gene deteo	ction				Multip	le gene de	tection			Pearson's
Carbapenem resistant G-ve bacteria (n=249)	bla _{CTX-M} n=111 (%)	bla _{TEM} n=86 (%)	bla _{SHV} n=43 (%)	bla _{NDM} n=3 (%)	bla _{IMP} n=6 (%)	bla _{CTX-M} +TEM n=33 (%)	bla _{CTX-M} +SHV n=26 (%)	bla _{TEM} +SHV n=3 (%)	bla _{CTX-M} +TEM+SHV n=6 (%)	bla _{TEM} +NDM n=2 (%)	bla _{TEM} +IMP n=1 (%)	bla _{CTX-M} +TEM+SHV +IMP n=2 (%)	Chi- square test
E. coli (n=157)	72 (45.85%)	56 <i>(35.65%)</i>	29 (18.5%)	0	0	15 (9.55%)	15 (9.55%)	0	6 (3.82%)	0	0	0	
K. pnuemoniae (n=45)	18 (40%)	14 <i>(31.1%)</i>	9 (20%)	1 (2.2%)	3 (6.7%)	14 <i>(31.1%)</i>	10 (22.2%)	3 (6.66%)	0	1 (2.22%)	0	0	
P. aeruginosa (n=20)	7 (35%)	8 (40%)	3 (15%)	0	2 (10%)	1 (5.0%)	1 (5.0%)	0	0	0	0	1 (5.0%)	<0.0001
P. mirabilis (n=17)	10 (58.8%)	6 (35.3%)	1 (5.9%)	0	0	3 (17.65%)	0	0	0	0	0	0	
A. baumannii (n=10)	4 (40%)	2 (20%)	1 (10%)	2 (20%)	1 (10%)	0	0	0	0	1 (10%)	1 (10%)	1 (10%)	

All the *A. baumannii* (n=10; 100%) had positive to the gene bla_{CTX-M} and bla_{TEM} , 20% (n=2) of the strains individually had the gene bla_{NDM} and bla_{SHV} , and the bla_{IMP} was detected in 10% of the *A. baumannii* isolates of the sputum samples. The gene combination $bla_{TEM+NDM}$, $bla_{TEM+IMP}$ and $bla_{CTX-M+TEM+SHV+IMP}$ were detected separately in 10% (n=1) of the strains. In none of the ESBL and carbapenem producers, the class D carbapenemase gene bla_{OXA-48} was not detected, and the above-mentioned details are given in Table 6; Fig <u>6</u>.

290

Fig 6. Frequency of detection of class A ESBL and class B & D carbapenemase encoding genes

in E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis and A. baumannii.

293 Genomic sequencing and phylogenetic tree relationships of the

294 *bla_{CTX-M}*

The gene bla_{CTX-M} was isolated and polymerized from the bacteria *E. coli* isolated from the urine sample. Partial gene sequencing of the bla_{CTX-M} was deposited in the GenBank, NCBI and obtained accession number 2780010. The cladogram of the phylogenetic tree was constructed using 99.74% similarity identification with various *E. coli* & *K. pneumoniae* bla_{CTX-M} genes which are already deposited in the GenBank, and the cladogram of the tree is given in Fig 7.

Fig 7. Cladogram of the phylogenetic tree of the class A ESBL gene *bla_{CTX-M}* isolated from the
ESBL *E. coli*.

303

304

305 **DISCUSSION**

Over the recent decades, the spread of ESBL producing *Enterobacteriaceae* has risen as a global concern because of substantial increases in mortality and morbidity and making it difficult to treat infections.[<u>30</u>] Reduced treatment options, complex infections, and costly treatments are some of the major concerns for people infected with ESBL-producing organisms [<u>31</u>]. A major driver of ESBL producing Gram-negative bacteria is the horizontal transfer of mobile genetic elements carrying genes for ESBL and/or carbapenemase enzyme production [<u>32</u>].

312 The present study collected 3670 various clinical samples, of which the urine samples were 313 predominantly (51.2%) received and had shown the highest bacterial growth rate (49.1%). The 314 bacterial growth rate was significant among the collected samples and the overall positivity rate of 315 the bacterial growth was 29.9%. Similarly, a study was carried out in Abu Dhabi [33] reported that 316 the urine sample was the most common sample type (24.2%), followed by sputum, wound and 317 blood respectively and Mahamat *et al.* stated that in their study the predominant clinical samples 318 were urine (72.5%) than other clinical samples and the highest bacterial growth (70.3%) rate was 319 observed from the urine samples [33, 34]

320 In this study, 64.3% of the bacterial isolates were gram-negative bacteria and remaining 35.7% 321 were gram positive bacteria (21.5%) and other gram variable bacteria & Candida species (14.2%). 322 Among the gram-negative bacteria, the E. coli (42.3%) was the most predominant isolates 323 followed by K. pneumoniae (19.4%), P. aeruginosa (13.5%), A. baumanii (7.3%) and P. mirabilis 324 (3.3%). Likewise, National AMR Surveillance system of the UAE reported (in 2020) that the E. 325 coli was the most commonly (80%) isolated gram-negative bacteria, then K. pneumoniae (55%-326 (60%), P. aeruginosa (20%), A. baumannii (<10%) and P. mirabilis (<5%) [35]. In our study, the 327 ESBL E. coli had shown 100% resistance to cefotaxime and ceftazidime, similarly, the study was

328 conducted by Al-Agamy et al. and Kabrah found 100% resistance to the same drugs by the ESBL 329 E. coli [36, 37]. High - medium resistance rates (97.5% - 46.5%) were detected to 11 different 330 antibiotics. The authors Kasim OA (2019), Shaaban et al. (2021) & Mohammed et al (2022) from 331 Bahrain, Alfaresi et al. (2018) & Karlowsky et al. (2022) from UAE were found that high-medium 332 resistance to the same drugs in their studies [38-42]. Lower resistance rate to gentamycin (14.7%), 333 tobramycin (12.7%), least resistance to cefoxitin (7.6%) and 100% sensitivity to 8 different 334 antibiotics which are mentioned in Table 4. Likely the Kasim OA, Perez-Lopez et al from Qatar 335 and Al-Tawfig et al. from Saudi Arabia were noted the same results in their studies [38, 43, 44]. 336 The ESBL K. pneumoniae were 100% resistant to ampicillin, aztreonam, cefazolin, cefepime and 337 cefuroxime. Multiples studies from different GCC region including UAE reported the pattern of 338 sensitivity to the same drugs [40, 42, 45-47]. Higher resistance rate (89%) was identified on 339 cefotaxime and amoxicillin+clavulanate and this was like the study from Bahrain [38], but lower - medium resistance rate was observed to the above drugs in various studies conducted in Kuwait, 340 341 UAE, Qatar and Saudi Arabia [37, 43, 47, 48]. The bacteria had shown lower resistance rate 342 (22.2%) to tigecycline, meropenem and other antibiotics and the studies from KSA [49, 50] 343 reported that the resistance rate has increased from 8% to 23.4% almost like the current study. The 344 resistant rate was 11.1% to colistin & imipenem and the rate has increased from 0% to 11.1% 345 during the past 5 years in UAE [41]. The P. mirabilis was 100% resistance and 100% sensitive to 10 and 8 different antibiotics respectively and are mentioned in the Table 4 and high - medium 346 347 resistance rate (76.5% - 53%) had identified to gentamycin, amikacin, ampicillin/sulbactam, 348 ciprofloxacin and norfloxacin. Rather JI et al. stated the same finding on the P. mirabilis [51]. But 349 in contrast, the current resistant rate was slightly higher than the study reported from China [52].

350 The bacteria *P. aeruginosa* were 100% resistant to 9 different drugs and 100% susceptible to 351 colistin and medium - low resistance rate was noted to piperacillin/tazobactam (65%) and 352 aztreonam (35%). In contrast to our study, the studies from Sudan [53] and Egypt [54] observed 353 that the bacteria had low resistance rate and high susceptible to the above-mentioned drugs. In the 354 case of A. baumannii, the bacteria were 100% resistant to 11 drugs which are given in the table 4, higher resistance rate (70% - 80%) was observed on the ampicillin/sulbactam & 355 356 trimethoprim/sulfamethoxazole and 30% resistance to colistin. This was very high resistance compared with studies from Oman [55] and Iran [56]. Resistance to the colistin is rapidly emerging 357 358 among the MDR A. baumannii and K. pneumoniae, which has become a global burden.

At present, more than 300 different ESBL variants have been identified, the CTX-M, SHV and TEM are the most reported in several areas of the world [57]. The UAE is considered among the GCC countries with the moderate rate of ESBL production among the *Enterobacteriaceae* [41, 58].

363 In the present study, all the 3 ESBL genes were detected in all the bacterial isolates. Among them, 364 the *bla_{CTX-M}* was predominantly harbored, mostly in the *E. coli* (45.9%), *P. mirabilis* (58.8%), *K.* 365 pneumoniae (42.2%), A. baumannii (40%) and P. aeruginosa (35%). Previous studies from 366 different countries in the GCC region, stated that the *bla_{CTX-M}* was the dominant gene among ESBL Enterobacterales (100%), E. coli (55.5%-100%) and K. pneumoniae (32.1% - 100%) across 367 different sample types and clinical settings [41,45,48,59,60]. After that *bla_{TEM}* and *bla_{SHV}* were the 368 369 next commonly detected genes and mainly in the E. coli (35.6% & 18.5%) and K. pneumoniae 370 (16.4% & 26.7%). Similarly in the UAE, Alfaresi et al. stated that the bla_{CTX-M} was the dominant 371 gene followed by *bla_{TEM}* and *bla_{SHV}* in their study and Eltai *et al.* found the same dominant gene 372 similarity in their study [41, 59]. In contrast to our results, a study from Iraq stated that the bla_{TEM}

373 was the most predominant gene in the *Enterobacterales* then followed by bla_{CTX-M} & bla_{SHV} .[61]

374 Likewise, Bajpai *et al.* also reported the same as the most prevalent gene was bla_{TEM} and the *bla_{SHV}*

375 [62] and in Zaki study the bla_{SHV} (61.22%) was the most detected gene [63].

376 The carbapenemase encoding gene *bla_{IMP}* was detected in 13.3% of *K. pneumoniae* isolated from 377 the urine samples and in 10% of A. baumannii from sputum & 10% of P. aeruginosa from both 378 the samples. Like this, 20% of the A. baumannii and 2.22% of K. pneumoniae harbored the bla_{NDM} 379 and they were isolated from the sputum samples. Almost 94% of them were positive to the bla_{IMP} 380 in Bharain [64] but 6% of the A. baumannii were positive to the bla_{NDM}. 8.7% of the K. pneumoniae 381 were positive to the *bla_{IMP}* in 2019, Saudi Arabia [46], Perez-Lopez *et al.* [43] reported that 3% of 382 E. coli & 2.4% of the E. coli were positive to the bla_{NDM} and bla_{OX4-48} respectively, and 12.9% & 383 3.2% of the K. pneumoniae were harbored the same genes. Moreover, the gene bla_{OX4-48} was 384 commonly identified among the Enterobacteriaceae in other countries including like Saudi Arabia 385 and Egypt [65-67]. However, in our study, none of the ESBL and the carbapenem resistant bacteria 386 harbored the gene *bla_{OX4-48}*. But in contrast to our study, Kamel NA *et al.* from Egypt reported that 387 6% E. coli, 9.4% Klebsiella spp, & 3.1% of each P. aeruginosa and A. baumannii were positive to 388 the bla_{NDM} and none of the gram-negative bacteria were carried the bla_{IMP} in their study, but they 389 were positive to the bla_{OXA-48} . [68]

The highest co-existence patterns were $bla_{CTX-M+TEM}$ and $bla_{CTX-M+SHV}$ represented by *E. coli* (9.6% of each), *K. pneumoniae* (31.1% & 22.2%) & *P. aeruginosa* (15% of each). In 17.65% of the *P. mirabilis* the only co-existence gene was $bla_{CTX-M+TEM}$. The lowest co-existence patterns were $bla_{TEM+SHV}$ & $bla_{CTX-M+TEM+SHV}$ represented by *K. pneumoniae* (6.67%) and *E. coli* (3.82%) respectively. Similarly, the highest co-existence of the gene $bla_{CTX-M+TEM}$ (21%) was found in the ESBL *E. coli* & *K. pneumoniae* from Qatar [59], Saudi Arabia [45, 69] and followed by the least

396 co-existence of the genes $bla_{TEM+SHV}$, $bla_{CTX-M+SHV}$ & $bla_{CTX-M+TEM+SHV}$ were detected in their same 397 studies, but in contrast, the Moglad et al, Badger-Emeka et al and Sid Ahmed et al found that the highest co-harbored genes were $bla_{CTX-M+TEM+SHV}$ (50% & 24.7%), $bla_{CTX-M+SHV}$ (50% & 10.1%) 398 399 found in the E. coli, K. pneumoniae and other Enterobacterales in their studies. [70,71] Likewise, 400 the lowest co-expression of the genes $bla_{TEM+NDM}$, $bla_{TEM+IMP}$ and $bla_{CTX-M+TEM+SHV+IMP}$ were also 401 detected in 2.22% K. pneumoniae, 5% P. aeruginosa and 10% of each A. baumannii to each gene 402 combination. In such a way, Elbadawi HS et al. found in their study that the lowest co-expression of the ESBL and carbapenemase producing genes were noticed in the K. pneumoniae, A. 403 404 baumannii, E. coli and P. aeruginosa. [72]

405 CONCLUSION

406 The current findings confirm UAE to have a slightly high prevalence of class A ESBL and class 407 B carbapenemase encoding genes. According to the study the gene bla_{CTX-M} , bla_{TEM} and bla_{SHV} 408 were the most detected in the E. coli and K. pneumoniae especially isolated from the urine samples. 409 The highest percentage of the bacteria K. pneumoniae harbored all the class A ESBL & class B 410 carbapenemase encoding genes and, the multiple two gene combinations like *bla_{CTX-M+TEM}*, *bla_{CTX}*. 411 M+SHV, bla_{TEM+SHV} & bla_{TEM+NDM} as well and then A. baumannii also harbored all the class A ESBL 412 and class B carbapenemase encoding genes and also they co-harbored the genes $bla_{TEM+NDM}$, $bla_{TEM+IMP}$, $bla_{CTX-M+TEM+SHV+IMP}$. The current results emphasize the significance of rational 413 414 antibiotic therapy and ongoing stringent surveillance and infection control strategies to 415 successfully curb the spread of these ESBL and carbapenemase encoding genes in the gram - ve 416 bacteria and become multidrug resistant pathogens.

417 Limitations of the study

- 418 As of all other studies this study also reported few limitations as follow.
- 419 a. The study samples received from various hospitals, clinics and Thumbay hospitals located in
- 420 and around the northern emirates of UAE (Fujairah, Umm-Al-Quwain, Ajman, and Sharjah)
- 421 and not received the samples from other emirates (Ras-Al-Khaimah, Dubai & Abu Dhabi).
- 422 b. The class D carbapenemase encoding gene bla_{OXA-48} was detected in none of the ESBL and
- 423 carbapenem resistant gram ve bacterial pathogens even in *A. baumannii*. In this study, partial
- 424 sanger sequencing of the predominant gene blaCTX-M was done but the other next
- 425 predominant class A genes bla_{TEM} & bla_{SHV} could not be able to do the sanger sequencing.

426 Supporting Information

- 427 Supplementary table 1a Test wells on the MicroScan Gram-negative panels (Neg Breakpoint
 428 Combo 50).
- 429 Supplementary table 1b Antibiotic sensitivity test wells on the MicroScan Gram-negative
 430 panels (Neg Breakpoint Combo 50).
- 431 S1 File. For each variable of interest, give sources of data and details of methods of assessment
- 432 (measurement). Describe comparability of assessment methods if there is more than one group.
- 433 S2 File. (a) Report numbers of individuals at each stage of study—e.g., numbers potentially
- 434 eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up,

435 and analyzed.

- 436 **S3 file.** Flow diagram of the study.
- 437 S4 File. Cross-sectional study—Report numbers of outcome events or summary measures.

438 S5 File. Cautious overall interpretation of results considering objectives, limitations, multiplicity
439 of analyses, results from similar studies, and other relevant evidence.

440 Acknowledgments

- 441 We would like to acknowledge the efforts of Physicians, Microbiologists and other relevant staffs
- 442 of Thumbay Laboratory and Thumbay University Hospital, Ajman, U.A.E for collecting the gram
- 443 -negative bacterial pathogens and data and conducting this study. Also want to express our
- gratitude to the College of Medicine, GMU for the constant support to conduct this research.

445 Author contributions

- 446 **Conceptualization:** Nazeerullah Rahamathullah
- 447 Data curation: Nazeerullah Rahamathullah, Premalatha Ragupathi, Vaneezeh Khamisani,
 448 Aisha Fadila Sadiq, Mariam Aylu Mobiddo.
- 449 Formal analysis: Premalatha Ragupathi, Vaneezeh Khamisani, Aisha Fadila Sadiq, Mariam
 450 Aylu Mobiddo.
- 451 Investigation: Nazeerullah Rahamathullah, Premalatha Ragupathi, Vaneezeh Khamisani,
- 452 Aisha Fadila Sadiq, Mariam Aylu Mobiddo.
- 453 Methodology: Nazeerullah Rahamathullah, Premalatha Ragupathi, Vaneezeh Khamisani,
- 454 Aisha Fadila Sadiq, Mariam Aylu Mobiddo, Alaa Kamian.
- 455 **Project administration:** Nazeerullah Rahamathullah, Nasir Parwaiz.
- 456 **Software:** Nazeerullah Rahamathullah, Premalatha Ragupathi, Vaneezeh Kasmian.

- 457 **Supervision:** Nazeerullah Rahamathullah, Mohammad Shahid Akhtar, Nasir Parwaiz.
- 458 Validation: Nazeerullah Rahamathullah, Sovan Bagchi.
- 459 Writing original draft: Premalatha Ragupathi, Vaneezeh Khamisani, Aisha Fadila Sadiq,
- 460 Mariam Aylu Mobiddo, Nazeerullah Rahamathullah, Sovan Bagchi.
- 461 Writing review & editing: Nazeerullah Rahamathullah, Sovan Bagchi.

462

463 **References**

1. McCarthy M. Woman dies after infection with bacteria resistant to all antibiotics available in

465 US. *BMJ*. 2017; 356:254. <u>https://doi.org/10.1136/bmj.j254</u> PMID: <u>28096073</u>.

- 466 2. de Kraker M.E.A.; Stewardson A.J.; Harbarth S. Will 10 Million People Die a Year due to
 467 Antimicrobial Resistance by 2050? *PloS Med.* 2016; 13(11):e1002184.
 468 https://doi.org/10.1371/journal.pmed.1002184 PMID: 27898664.
- 3. Breijyeh Z.; Jubeh B.; Karaman R. Resistance of Gram-Negative Bacteria to Current
 Antibacterial Agents and Approaches to Resolve It. *Molecules*. 2020; 25(6),1340.
 https://doi.org/10.3390/molecules25061340 PMID: 32187986.
- 472 4. Tooke C.L.; Hinchliffe P.; Bragginton E.C.; Colenso C.K.; Hirvonen V.H.A.; Takebayashi
- 473 Y.; et al. β -Lactamases and β -Lactamase Inhibitors in the 21st Century. *J Mol Biol*. 2019;
- 474 431(18): 3472-3500. <u>https://doi.org/10.1016/j.jmb.2019.04.002</u> PMID: 30959050.
- 475 5. Exner M.; Bhattacharya S.; Christiansen B.; Gebel J.; Gbermes P.G.; Hartemann P.; et al.
- 476 Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?
- 477 GMS Hygiene and Infection Control. 2017; 12:1-24. <u>https://doi.org/10.3205/dgkh000290</u>
- 478 PMID: <u>28451516</u>.

- 479 6. Rawat D.; Nair D. Extended-spectrum β-lactamases in Gram Negative Bacteria. *J Glob Infect*
- 480 *Dis.* 2010; 2(3):263. <u>https://doi.og/10.4103/0974-777x.68531</u> PMID: <u>20927289</u>.
- 481 7. Hawkey P.M.; Jones A.M. The changing epidemiology of resistance. *J Antimicrob*482 *Chemother*. 2009; 64, Suppl. 1, i3–i10. https://doi.org/10.1093/jac/dkp256 PMID: 19675017.
- 483 8. Ambler R.P. The structure of beta-lactamases. *Philos Trans R Soc Lond B Biol Sci.* 1980;
- 484 289(1036):321-31. https://doi.og/10.1098/rstb.1980.0049 PMID: 6109327.
- 485 9. Ambler R.P.; Coulson A.F.; Frère J.M.; Ghuysen J.M.; Joris B.; Forsman M.; et al. A standard
- 486 numbering scheme for the class A beta-lactamases. Biochem J. 1991; 276 (1)(1):269-70.
- 487 <u>https://doi.org/10.1042/bj2760269</u> PMID: <u>2039479</u>.
- 488 10. Bush K.; Jacoby G.A. Updated Functional Classification of β-Lactamases. *Antimicrob Agents* 489 *Chemother*. 2010; 54 (3):969-976. https://doi.org/10.1128/aac.01009-09 PMID: 19995920.
- 490 11. Kong K.F.; Schneper L.; Mathee K. Beta-lactam Antibiotics: From Antibiosis to Resistance
- 491 and Bacteriology. *APMIS*. 2010; 118(1):1-36. <u>https://doi.org/10.1111/j.1600-</u>
 492 0463.2009.02563.x PMID: 20041868.
- 493 12. Kapoor G.; Saigal S.; Elongavan A. Action and resistance mechanisms of antibiotics: A guide
 494 for clinicians. *J Anaesthesiol Clin Pharmacol.* 2017; 33(3):300-305.
 495 https://doi.org/10.4103/joacp.JOACP_349_15 PMID: 29109626.
- 496 13. Zhao W.H.; Hu Z.Q. Epidemiology and genetics of CTX-M extended-spectrum β-lactamases
- 497 in Gram-negative bacteria. *Crit Rev Microbiol.* 2013; 39(1):79-101.
 498 https://doi.org/10.3109/1040841X.2012.691460 PMID: 22697133.
- 499 14. Bernard H.; Tancrede C.; Livrelli V.; Morand A.; Barthelemy M.; Labia R. A novel plasmid500 mediated extended-spectrum b-lactamase not derived from TEM- or SHV-type enzymes. J.

- 501 Antimicrob. Chemother. 1992; 29, 590–592. <u>https://doi.org/10.1093/jac/29.5.590</u> PMID:
 502 <u>1624397</u>.
- 503 15. Ahmed A.R.; Neveen A.A.; Magdy A.A.; Ramy K.A. Novel *bla*CTX-M variants and
 504 genotype-phenotype correlations among clinical isolates of extended spectrum beta505 lactamase-producing *Escherichia coli*. *Sci Rep*. 2019; 9(1):4224.
 506 https://doi.org/10.1038/s41598-019-39730-0 PMID: 30862858.
- 507 16. Dionysios A.A.; Rida A.; Karam A.R.; Thomas B.; Christopher B.; Neal C.; et al. PATRIC as
- a unique resource for studying antimicrobial resistance. *Briefings in Bioinformatics*. 2019;
- 509 20(4):1094–1102. <u>https://doi.org/10.1093/bib/bbx083</u> PMID: <u>28968762</u>.
- 510 17. Chong Y.; Shimoda S.; Shimono N. Current epidemiology, genetic evolution and clinical
- 511 impact of extended-spectrum β-lactamase-producing *Escherichia coli* and *Klebsiella*512 *pneumoniae*. *Infect Genet Evol*. 2018; 61:185-188.
- 513 https://doi.org/10.1016/j.meegid.2018.04.005 PMID: 29626676.
- 514 18. Livermore D.M. Has the era of untreatable infections arrived? *J Antimicrob Chemother*. 2009;
 515 64(1): 29-36. https://doi.org/10.1093/jac/dkp255 PMID: 19675016.
- 516 19. Mahony M.; McMullan B.; Brown J.; Kennedy S.E. Multidrug-resistant organisms in urinary
- 517 tract infections in children. *Pediatr Nephrol.* 2020; 35(9):1563-1573.
 518 <u>https://doi.org/10.1007/s00467-019-04316-5</u> PMID: <u>31418063</u>.
- 519 20. Cantón R.; Akóva M.; Carmeli Y.; Giske C.G.; Glupczynski Y.; Gniadkowski M.; et al. Rapid
- 520 evolution and spread of carbapenemases among Enterobacteriaceae in Europe. *Clin Microbiol*
- 521 Infect. 2012; 18(5). https://doi.org/10.1111/j.1469-0691.2012.03821.x PMID: 22507109.

- 522 21. Poirel L.; Pitout J.D.; Nordmann P. Carbapenemases: molecular diversity and clinical
 523 consequences. *Future Microbiol.* 2007; 2(5). <u>https://doi.org/10.2217/17460913.2.5.501</u>
 524 PMID: 17927473.
- 525 22. Steinmann J.; Kaase M.; Gatermann S.; Popp W.; Steinmann E.; Damman M.; et al. Outbreak
- 526 due to a *Klebsiella pneumoniae* strain harboring KPC-2 and VIM-1 in a German university
- 527 hospital, July 2010 to January 2011. *Euro Surveill*. 2011; 16(33):19944.
 528 <u>https://pubmed.ncbi.nlm.nih.gov/21871227/</u> PMID: <u>21871227</u>.
- 529 23. Tufa T.B; Mackenzie C.R; Orth H.M; Wienemann O; Nordmann T; Abdissa S. et al.
- 530 Prevalence and characterization of antimicrobial resistance among gram-negative bacteria
- isolated from febrile hospitalized patients in central Ethiopia. *Antimicrob Resist Infect Control.* 2022; 11(1):8:1-12. https://doi.org/10.1186/s13756-022-01053-7 PMID: 35033191.
- 533 24. Tofteland S.; Haldorsen B.; Dahl K.H; Simonsen G.S.; Steinbakk M; Walsh T.R; et al.
- 534 Norwegian ESBL Study Group: Effects of phenotype and genotype on methods for detection
- 535 of extended-spectrum-beta-lactamase-producing clinical isolates of *Escherichia coli* and
- 536 *Klebsiella pneumoniae* in Norway. *J Clin Microbiol*. 2007; 45:199–205.
 537 https://doi.org/10.1128/JCM.01319-06 PMID: 17079502.
- 538 25. Murray P.R.; Baron E.J.; Jorgensen J.H; Landry M.L; Pfaller M.A. Detection and
 539 characterization of antimicrobial resistance genes in pathogenic bacteria. In Manual of
 540 Clinical Microbiology. *American Society for Microbiology* 2007; 9:1250-1256.
- 541 26. Nordmann P; Naas T; Poirel L. Global spread of carbapenemase-producing
 542 Enterobacteriaceae. Emerging infectious diseases. 2011; 17(10):1791.
 543 https://doi.org/10.3201/eid1710.110655 PMID:22000347.

32

- 544 27. Poirel L; Walsh T.R; Cuvillier V; Nordmann P. Multiplex PCR for detection of acquired
- 545 carbapenemase genes. Diagnostic microbiology and infectious disease. 2011; 70(1):119-23.

546 https://doi.org/10.1016/j.diagmicrobio.2010.12.002 PMID: 21398074.

- 547 28. Atschul S.F; Madden T.L; Schaffer A.A; Zhang J; Zhang Z; Miller W. et al. Gapped BLAST
- and PSI-BLAST. A new generation of protein database search programs. NucleicAcid Res.
- 549 1997; 25(17): 3389–3402. https://doi.org/10.1093/nar/25.17.3389 PMID: <u>9254694</u>.
- 550 29. Khakabimamaghani S, Najafi A, Ranjbar R, Raam M. GelClust: a software tool for gel
 551 electrophoresis images analysis and dendrogram generation. *Comput Methods Programs*
- 552 *Biomed.* 2013; 111(2):512–8. https://doi.org/10.1016/j.cmpb.2013.04.013 PMID: 23727299.
- 553 30. Naylor N.R.; Atun R.; Zhu N.; Kulasabanathan K.; Silva S.; Chatterjee A.; et al. Estimating
- the burden of antimicrobial resistance: a systematic literature review. *Antimicrob. Resist. Infect. Control.* 2018; 7(58):1-17. <u>https://doi.org/10.1186/s13756-018-0336-y</u> PMID:
 29713465.
- 31. Maslikowska J.A.; Walker S.A.; Elligsen M.; Mittmann N.; Palmay L.; Daneman N.; et al.
 Impact of infection with extended-spectrum beta-lactamase-producing *Escherichia coli* or *Klebsiella* species on outcome and hospitalization costs. *J. Hosp. Infect.* 2016; 92, 33–41.
- 32. Ruppé É.; Woerther P.L.; Barbier F. Mechanisms of antimicrobial resistance in Gramnegative bacilli. *Ann Intensive Care*. 2015; 5:21:1-15. <u>https://doi.org/10.1186/s13613-015-</u>
 0061-0 PMID: 26261001.
- 563 33. Pál T.; Butt A.B.; Ghazawi A.; Jens Thomsen J.; Rizvi T.A.; Sonnevend A. Early Years of
 564 Carbapenem-Resistant Enterobacterales Epidemic in Abu Dhabi. *Antibiotics*. Antibiotics
 565 2022; 11:1435:1-11. https://doi.org/10.3390/antibiotics11101435 PMID: 36290093.

33

- 34. Mahamat O.O.; Lounnas M.; Hide M.; Dumont Y.; Tidjani A.; Kamougam K.; et al. High
 prevalence and characterization of extended-spectrum ß-lactamase producing
 Enterobacteriaceae in Chadian hospitals. *BMC Infect Dis.* 2019; 19(1):205:1-7.
 https://doi.org/10.1186/s12879-019-3838-1 PMID: 30819135.
- 570 35. U.A.E Ministry of Health and Prevention. United Arab Emirates Surveillance of
 571 Antimicrobial Resistance Annual Report. 2022.
 572 <u>https://mohap.gov.ae/assets/f5a5705/National%20AMR%20Surveillance%20Report%20202</u>
 573 2%20MOHAP 638205230312192483.pdf.aspx
- 36. Al-Agamy M.H.; Aljallal A.; Radwan H.H.; and Shibl A.M. Characterization of
 carbapenemases, ESBLs, and plasmid-mediated quinolone determinants in carbapeneminsensitive *Escherichia coli* and *Klebsiella pneumoniae* in Riyadh hospitals. *J. Infect. Public*
- 577 *Health.* 2018; 11, 64–68. <u>https://doi.org/10.1016/j.jiph.2017.03.010</u> PMID: <u>28462854</u>.
- 578 37. Kabrah A. Extended-spectrum beta-lactamase and carbapenem-resistant gram-negative
 579 pathogens in makkah, Saudi Arabia. *Ethiop J. Health Sci.* 2022; 32 (6): 1221–1230.
 580 https://doi.org/10.4314/ejhs.v32i6.20 PMID: 36475249.
- 38. Ardati K.O.; Chacko S.T.; Jagtap A.; and Jacob S. Prevalence of bacterial pathogens and
 antimicrobial susceptibility pattern in Bahrain tertiary care hospital. *J. Bahrain Med. Soc.*
- 583 2019; 31: 5–16. <u>https://doi.org/10.26715/jbms.31_06032019</u>
- 584 39. Shaaban O.A.; Mahmoud N.A.; Zeidan A.A.; Kumar N.; Finan A.C. Prevalence and resistance
- patterns of pediatric urinary tract infections in Bahrain. *Cureus*. 2021; 13: e20859:1-10.
- 586 <u>https://doi.org/10.7759/cureus.20859</u> PMID: <u>35141098</u>.

- 587 40. Mohammed D.; Isa H.M.; Ali, M.F. Microbial etiology and antibiotic resistance patterns of
- urinary tract pathogens in hospitalized infants in Bahrain: a tertiary care center experience.
- 589 *Cureus*. 2022; 16:14(9):e29236. <u>https://doi.org/10.7759/cureus.29236</u> PMID: <u>36277545</u>.
- 590 41. Alfaresi M.; Kim Sing G.; Senok A. First report of *bla_{CTX-M-28}* in Enterobacteriaceae isolates in
- the United Arab Emirates. J. Pathog. 2018; 1304793. <u>https://doi.org/10.1155/2018/1304793</u>
 PMID: 29593911.
- 593 42. Karlowsky J.A.; Lob S.H.; Deryke C.A.; Siddiqui F.; Young K.; Motyl M.R.; et al. Prevalence
- 594 of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates
- 595 collected by the SMART global surveillance program from 2015 to 2019. *Int. J. Antimicrob.*
- 596 Agents. 2022; 59, 106535. <u>https://doi.org/10.1016/j.ijantimicag.2022.106535</u> PMID:
 597 29593911.
- 43. Perez-Lopez A.; Sundararaju S.; Al-Mana H.; Tsui K.M.; Hasan MR.; Suleiman M.; et al.
- 599 Molecular characterization of extended-spectrum beta-Lactamase-Producing *Escherichia coli*
- and *Klebsiella pneumoniae* among the pediatric population in Qatar. *Front. Microbiol.* 2020;
- 601 11: 581711. <u>https://doi.org/10.3389/fmicb.2020.581711</u> PMID: <u>33262745</u>.
- 602 44. Al-Tawfiq J.A.; Rabaan A.A.; Saunar J.V.; Bazzi A.M. Antimicrobial resistance of gram-
- 603 negative bacteria: a six-year longitudinal study in a hospital in Saudi Arabia. J. Infect. Public
- 604 *Health*. 2020; 13:737–745. <u>https://doi.org/10.1016/j.jiph.2020.01.004</u> PMID: <u>32008927</u>.
- 45. Ibrahim M.E.; Algak T.B.; Abbas M.; Elamin B.K. Emergence of *bla_{TEM}*, *bla_{CTX-M}*, *bla_{SHV}* and
- 606 *bla_{OXA}* genes in multidrug-resistant *Enterobacteriaceae* and *Acinetobacter baumannii* in Saudi
- 607 Arabia. Exp. Ther. Med. 2021; 22(6):1450. <u>https://doi.org/10.3892/etm.2021.10885.1450</u>
- 608 PMID: <u>34721692</u>.

- 609 46. Azim N.S.A.; Nofal M.Y.; Alharbi M.A.; Al-Zaban M.I.; Somily A.M. Molecular-diversity,
- 610 prevalence and antibiotic susceptibility of pathogenic *Klebsiella pneumoniae* under Saudi
- 611 condition. *Pak J. Biol. Sci.* 2019; 22(4):174–179. https://doi.org/10.3923/pjbs.2019.174.179
- 612 PMID: <u>31930818</u>.
- 613 47. Dash N.R.; Albataineh M.T.; Alhourani N.; Khoudeir A.M.; Ghanim M.; Wasim M.; et al.
- 614 Community-acquired urinary tract infections due to extended-spectrum b-lactamase-producing
- 615 organisms in United Arab Emirates. *Travel Med. Infect. Dis.* 2018; 22:46–50.
 616 https://doi.org/10.1016/j.tmaid.2018.01.007 PMID: 29409967.
- 617 48. Al-Sweih N.; Jamal W.; Mokaddas E.; Habashy N.; Kurdi A.; Mohamed N. Evaluation of the
- 618 in vitro activity of ceftaroline, ceftazidime/avibactam and comparator antimicrobial agents
 619 against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012-19. *JAC*
- 620 Antimicrob. Resist. 2021; 3(4):1-10. <u>https://doi.org/10.1093/jacamr/dlab159</u> PMID:
 621 36479234.
- 622 49. Aldrazi F.A.; Rabaan A.A.; Alsuliman S.A.; Aldrazi H.A.; Alabdalslam M.J.; Alsadiq S.A.; et
- al. ESBL expression and antibiotic resistance patterns in a hospital in Saudi Arabia: do
 healthcare staff have the whole picture? *J. Infect. Public Health.* 2020; 13(5): 759–766.
 https://doi.org/10.1016/j.jiph.2019.12.001 PMID: 31901487.
- 626 50. Jalal N.A.; Al-Ghamdi A.M.; Momenah A.M.; Ashgar S.S.; Bantun F.; Bahwerth F.S.; et al.
- 627 Prevalence and antibiogram pattern of klebsiella pneumoniae in a tertiary care hospital in
- makkah, Saudi Arabia: an 11-year experience. *Antibiotics (Basel)* 2023; 12(1):164.
 https://doi.org/10.3390/antibiotics12010164 PMID: 36671365.
- 630 51. Rather J.I.; Mohiuddin Z.; Syed F.N.; Haris M.; Nabi M.; Farooq A.; et al. Gram-Negative
- 631 Extended Spectrum Beta-Lactamase Producing Bacteria Prevalence in Jouf Region Tertiary

- 632 Care Hospital, Saudi Arabia. J Pure Appl Microbiol. 2021; 15(1):421-427.
 633 https://doi.org/10.22207/JPAM.15.1.39.
- 634 52. Mo L.; Wang J.; Qian J.; Peng M. Antibiotic Sensitivity of Proteus mirabilis Urinary Tract
- 635 Infection in Patients with Urinary Calculi. Int J Clin Pract. 2022; 2022: 7273627.
- 636 <u>https://doi.org/10.1155/2022/7273627</u> PMID: <u>36628152</u>.
- 637 53. Omer T.H.S.; Mustafa S.A.M.; Mohamed S.O.O. Extended Spectrum β-Lactamase-Mediated
- 638 Resistance and Antibiogram of *Pseudomonas aeruginosa* Isolates from Patients Attending
- Two Public Hospitals in Khartoum, Sudan. Int J Microbiol. 2020; 2020: 2313504.
- 640 <u>https://doi.org/10.1155/2020/2313504</u> PMID: <u>33163076</u>.
- 54. Elhariri M.; Hamza D.; Elhelw R.; Dorgham S.M. Extended-spectrum
 beta-lactamase-producing *Pseudomonas aeruginosa* in camel in Egypt: potential human
 hazard. *Ann Clin Microbiol Antimicrob*. 2017; 16(1):21. <u>https://doi.org/10.1186/s12941-017-</u>
- 644 <u>0197-x</u> PMID: <u>28359312</u>.
- 645 55. Sannathimmappa M.B.; Nambiar V.; Aravindakshan R. Antibiotic Resistance Pattern of
- 646 Acinetobacter baumannii Strains: A Retrospective Study from Oman. Saudi J Med Med Sci.
- 647 2021; 9(3):254-60. <u>https://doi.org/10.4103/sjmms.sjmms_855_20</u> PMID: <u>34667473</u>.
- 56. Tashkan B.B.; Niakan M.; Khaledi M.; Afkhami H.; Sameni F.; Shahriar Bakhti S.; et al.
 Antibiotic resistance assessment of *Acinetobacter baumannii* isolates from Tehran hospitals
 due to the presence of efflux pumps encoding genes (adeA and adeS genes) by molecular
 method. *BMC Res Notes.* 2020; 13(1):543. <u>https://doi.org/10.1186/s13104-020-05387-6</u>
 PMID: 33213526.

653	57. Paterson D.L.; Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin
654	Microbiol Rev. 2005; 18(4):657-86. https://doi.org/10.1128/CMR.18.4.657-686.2005 PMID:
655	<u>16223952</u> .

- 656 58. Naira A.; Majeed B.; Begum H.; Rukshana N.; Rahamathullah N.; Khan Z.A. Prevalence of
- 657 Extended-Spectrum of Beta-Lactamase-producing class a genes in *Escherichia coli* and
- *Klebsiella pneumoniae* isolated from patients urine samples in United Arab Emirates. *International Journal of Health Sciences.* 2022; 6(S5):4577–4587.
- 660 <u>https://doi.org/10.53730/ijhs.v6nS5.10081</u>.
- 661 59. Eltai N.O.; Al-Thani A.A.; Al-Ansari K.; Deshmukh A.S.; Wehedy E.; Al-Hadidi S.H.; et al.
- 662 Molecular characterization of extended spectrum β -lactamases enterobacteriaceae causing
- 663 lower urinary tract infection among pediatric population. *Antimicrob Resist Infect Control.*
- 664 2018; 7:90. https://doi.org/10.1186/s13756-018-0381-6 PMID: 30069306.
- 60. Azab K.S.M.; Abdel-Rahman M.A.; El-Sheikh H.H.; Azab E.; Gobouri A.A.; Farag M.M.S.;
- 666 Distribution of extended-spectrum beta-lactamase (ESBL)-encoding genes among multidrug-
- 667 resistant gram-negative pathogens collected from three different countries. *Antibiotics (Basel)*.
- 668 2021; 10(3): 247. <u>https://doi.org/10.3390/antibiotics10030247</u> PMID: <u>3380141810</u>.
- 669 61. Pishtiwan A.H.; Khalil Mustafa Khadija K.M. Prevalence of *blaTEM*, *blaSHV*, and *blaCTX*-
- 670 *M* Genes among ESBL-Producing *Klebsiella pneumoniae* and *Escherichia coli* Isolated from
- 671 Thalassemia Patients in Erbil, Iraq. *Mediterr J Hematol Infect Dis.* 2019; 11(1):e2019041.
 672 https://doi.org/10.4084/MJHID.2019.041 PMID: 31308917.
- 673 62. Bajpai T.; Pandey M.; Varma M.; Bhatambare G.S. Prevalence of TEM, SHV, and CTX-M
- Beta-Lactamase genes in the urinary isolates of a tertiary care hospital. *Avicenna J Med.* 2017;
- 675 7(1):12-6. <u>https://doi.org/10.4103/2231-0770.197508</u> PMID: <u>28182026</u>.

- 676 63. Zaki M.; El-Halaby H.; Elmansoury E.; Zeid M.; Khaled K.; Nomir M. Genetic Study of
- 677 Extended Spectrum Beta-Lactamase and Carbapenemase Producing *Escherichia coli* Causing
- 678 Sepsis among Egyptian Children. *The Open Microbiology Journal* 2019; 13: 128-137.
- 679 https://doi.org/10.2174/1874285801913010128. PID: TOMICROJ-13-128.
- 680 64. Al-Rashed N.; Bindayna K.M.; Mohammad Shahid M.; Saeed NK.; Darwish A,; Joji R.M; et
- al. Prevalence of Carbapenemases in Carbapenem-Resistant *Acinetobacter baumannii* Isolates
- 682 from the Kingdom of Bahrain. *Antibiotics*. 2023; 12:1198.
 683 https://doi.org/10.3390/antibiotics12071198 PMID: 37508294.
- 684 65. Zaman T.U.; Aldrees M; Al Johani S.M.; Alrodayyan M; Aldughashem F.A.; Balkhy H.H.
- 685 Multi-drug carbapenem- resistant *Klebsiella pneumoniae* infection carrying the OXA-48
- gene and showing variations in outer membrane protein 36 causing an outbreak in a tertiary
- 687 care hospital in Riyadh, Saudi Arabia. *International Journal of Infectious Diseases*. 2014;
- 688 28:186–192. https://doi.org/10.1016/j.ijid.2014.05.021 PMID: 25245001
- 689 66. Memish Z.A.; Assiri A.; Almasri M.; Roshdy H.; Hathout H.; Kaase M.; et al. Molecular
- 690 characterization of carbapenemase production among gram-negative bacteria in Saudi
- 691 Arabia. *Microbial Drug Resistance*. 2015; 21(3):307–314.
- 692 https://doi.org/10.1089/mdr.2014.0121 PMID: 25569024
- 693 67. Nordmann P.; Poirel L.; Carrer A.; Toleman M.A.; Walsh T.R. How to detect NDM-1
 694 producers. *Journal of clinical microbiology*. 2011; 49(2):718–721.
 695 https://doi.org/10.1128/JCM.01773-10 PMID: 21123531.
- 68. Kamel K.A.; El-Tayeb W.N.; El-Ansary M.R.; Mansour M.T.; Aboshanab K.M. Phenotypic
 screening and molecular characterization of carbapenemase-producing Gram-negative bacilli
 recovered from febrile neutropenic pediatric cancer patients in Egypt. *PLoS One*. 2018;

699 13(8):0202119. <u>https://doi.org/10.1371/journal.pone.0202119</u> PMID: <u>30157188</u>.

- 700 69. Moglad E.; Alanazi N.; Altayb H.N.; Genomic Study of Chromosomally and Plasmid-
- 701 Mediated Multidrug Resistance and Virulence Determinants in Klebsiella Pneumoniae Isolates
- 702 Obtained from a Tertiary Hospital in Al-Kharj, KSA. *Antibiotics (Basel)*. 2022; 11(11):1564.
- 703 https://doi.org/10.3390/antibiotics11111564 PMID: 36358219.
- 70. Badger-Emeka L.I.; Kausar N.; Estrella E.; Angeles G.B. A three-year look at the phylogenetic
- profile, antimicrobial resistance, and associated virulence genes of uropathogenic *Escherichia*
- 706 *coli. Pathogens.* 2022; 11(6):631. <u>https://doi.org/10.3390/pathogens11060631</u> PMID:
- 707 <u>35745485</u>.
- 708 71. Sid-Ahmed M.A.; Bansal D.; Acharya A.; Elmi A.A.; Hamid J.M.; Sid Ahmed A.M.; et al 709 Antimicrobial susceptibility and molecular epidemiology of extended-spectrum beta-710 lactamase-producing Enterobacteriaceae from intensive care units at Hamad Medical 2016; 711 Corporation, Antimicrob. 5:4. Qatar. Resist. Infect. Control 712 https://doi.org/10.1186/s13756-016-0103-x PMID: 26865975.
- 713 72. Elbadawi H.S.; Elhag K.M.; Mahgoub E.; Altayb H.N.; Ntoumi F.; et al. Detection and
 714 characterization of carbapenem resistant Gram-negative bacilli isolates recovered from
 715 hospitalized patients at Soba University Hospital, Sudan. *BMC Microbiol.* 2021; 21(1):136.
- 716 <u>https://doi.org/10.1186/s12866-021-02133-1</u> PMID: <u>33947325</u>.




Fig 1. Detection of blaCTX-M, blaTEM, blaSHV, blaIMP & blaNDM




Fig 2. No. of Gram -ve and gram +ve bacteria isolated from vario




Fig 3. Total no. of E. coli, K. pneumoniae, P. aeruginosa, P. mirabil




Fig 4. Heatmap of antibiotic sensitivity pattern




Fig 5. Heatmap of frequency of class A ESBL and class B carbape




Fig 6. Frequency of detection of class A ESBL and class B & D car




Fig 7. Cladogram of the phylogenetic tree of the clas